MED28 and prostate cancer: However, cancer genomics data, where MED28 was found to be amplified in various cancers, including breast cancer, ovarian cancer, pancreatic cancer, sarcoma, lung adenoma, prostate cancer, and melanoma, clearly indicate that the overexpression of MED28 is closely related to cancer progression (Supplementary Figure S4A).